Besides natural sunlight and expensive artificial lights, economical indoor white light can play a significant role in activating a catalyst for photocatalytic removal of organic toxins from contaminated water. In the current effort, CeO has been modified with Ni, Cu, and Fe through doping methodology to study the removal of 2-chlorophenol (2-CP) in the illumination of 70 W indoor LED white light. The absence of additional diffractions due to the dopants and few changes such as reduction in peaks' height, minor peak shift at 2θ (28.525°) and peaks' broadening in XRD patterns of modified CeO verifies the successful doping of CeO. The solid-state absorption spectra revealed higher absorbance of Cu-doped CeO whereas a lower absorption response was observed for Ni-doped CeO. An interesting observation regarding the lowering of indirect bandgap energy of Fe-doped CeO (∼2.7 eV) and an increase in Ni-doped CeO (∼3.0 eV) in comparison to pristine CeO (∼2.9 eV) was noticed. The process of - recombination in the synthesized photocatalysts was also investigated through photoluminescence spectroscopy. The photocatalytic studies revealed the greater photocatalytic activity of Fe-doped CeO with a higher rate (∼3.9 × 10 min) among all other materials. Moreover, kinetic studies also revealed the validation of the Langmuir-Hinshelwood kinetic model (R = 0.9839) while removing 2-CP in the exposure of indoor light with a Fe-doped CeO photocatalyst. The XPS analysis revealed the existence of Fe, Cu and Ni core levels in doped CeO. Using the agar well-diffusion method, the antifungal activity was assessed against the fungus and . Compared to CeO, Ni-doped CeO, and Cu-doped CeO nanoparticles, the Fe-doped CeO nanoparticles have outstanding antifungal properties.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186159 | PMC |
| http://dx.doi.org/10.3389/fchem.2023.1126171 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of the User-Centered "Healthcare CEO" App for Patients With Type 1 Diabetes Transitioning From Adolescence to Early Adulthood: Protocol for a Randomized Controlled Trial.
JMIR Res Protoc
January 2025
Department of Public Health and Primary Care, KU Leuven-University of Leuven, Leuven, Belgium.
Background: Young patients aged 16 to 25 years with type 1 diabetes (T1D) often encounter challenges related to deteriorating disease control and accelerated complications. Mobile apps have shown promise in enhancing self-care among youth with diabetes. However, inconsistent findings suggest that further evidence is necessary to confirm the effectiveness of app-based interventions.
View Article and Find Full Text PDFIntroducing the Next Era in Assessment.
Perspect Med Educ
January 2025
A Professor at the Medical College of Wisconsin, Wisconsin, USA.
In this introduction, the guest editors of the "Next Era in Assessment" special collection frame the invited papers by envisioning a next era in assessment of medical education, based on ideas developed during a summit that convened professional and educational leaders and scholars. The authors posit that the next era of assessment will focus unambiguously on serving patients and the health of society, reflect its sociocultural context, and support learners' longitudinal growth and development. As such, assessment will be characterized as transformational, development-oriented and socially accountable.
View Article and Find Full Text PDFEvaluating Digital Rehabilitation Outcomes in Chronic Musculoskeletal Conditions Across Non-Obesity, Obesity, and Severe Obesity.
J Pain Res
January 2025
Sword Health, Inc, Draper, Utah, USA.
Background: Obesity is a known risk factor and aggravator of musculoskeletal (MSK) conditions. The rising prevalence of obesity calls for scalable solutions to address MSK conditions in this population, given their complex clinical profile and barriers to accessing care.
Purpose: To evaluate the engagement and clinical outcomes of a fully remote digital care program in patients with MSK conditions, focusing on those with and without comorbid obesity.
CeO@CA-074Me Nanoparticles Alleviate Inflammation and Improve Osteogenic Microenvironment by Regulating the CTSB-NLRP3 Signaling Pathway.
Int J Nanomedicine
January 2025
Department of Stomatology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, People's Republic of China.
Background: It is well established that the interaction between osteogenesis and inflammation can impact bone tissue regeneration. The use of nanoparticles to treat and alleviate inflammation at the molecular level has the potential to improve the osteogenic microenvironment and serve as a therapeutic approach.
Methods: We have synthesized new hollow cerium oxide nanoparticles and doped with cathepsin B inhibitor (CA-074Me) to create novel CeO@CA-074Me NPs.
Measuring health-related quality of life in cardiovascular disease using a novel patient-centred and disease-specific patient-reported outcome measure.
Int J Cardiol Cardiovasc Risk Prev
March 2025
Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Background: Assessment of health-related quality of life (HRQoL) in patients with cardiovascular disease (CVD) is impaired by limitations of current patient-reported outcome measures (PROMs). We developed the first cardiovascular disease (CVD) specific electronic PROM for which health items were derived by a fully patient-centered method. This paper reports on the measurement of HRQoL in CVD patients by a novel developed electronic patient-centred PROM based on a preference-based measurement model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!